MX2015016494A - Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa. - Google Patents

Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa.

Info

Publication number
MX2015016494A
MX2015016494A MX2015016494A MX2015016494A MX2015016494A MX 2015016494 A MX2015016494 A MX 2015016494A MX 2015016494 A MX2015016494 A MX 2015016494A MX 2015016494 A MX2015016494 A MX 2015016494A MX 2015016494 A MX2015016494 A MX 2015016494A
Authority
MX
Mexico
Prior art keywords
methods
xanthine oxidase
patient
compositions
treatment
Prior art date
Application number
MX2015016494A
Other languages
English (en)
Inventor
Gunawardhana Lhanoo
Gupte Vijay
Naik Himanshu
Mayer Michael
Komatsu Kanji
Original Assignee
Takeda Pharmaceuticals Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Usa Inc filed Critical Takeda Pharmaceuticals Usa Inc
Publication of MX2015016494A publication Critical patent/MX2015016494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente, se describen métodos y composiciones farmacéuticas para reducir el número de brotes de gota experimentados por un paciente. Los métodos pueden comprender administrar a un paciente con hiperuricemia una cantidad efectiva de un inhibidor de xantina oxidasa en una forma de dosificación de liberación modificada una vez al día o en una forma de dosificación de liberación modificada una vez al día o en una forma de dosificación de liberación inmediata dos o más veces al día para evitar al menos un brote de gota experimentados por el paciente.
MX2015016494A 2013-05-31 2014-05-30 Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa. MX2015016494A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361829759P 2013-05-31 2013-05-31
US201361839609P 2013-06-26 2013-06-26
PCT/US2014/040286 WO2014194226A2 (en) 2013-05-31 2014-05-30 Methods of treatment and compositions with xanthine oxidase inhibitors

Publications (1)

Publication Number Publication Date
MX2015016494A true MX2015016494A (es) 2016-11-18

Family

ID=50983231

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015016494A MX2015016494A (es) 2013-05-31 2014-05-30 Métodos de tratamiento y composiciones con inhibidores de xantina oxidasa.

Country Status (9)

Country Link
US (2) US20140357683A1 (es)
JP (2) JP2016520133A (es)
CN (1) CN105579037A (es)
CA (1) CA2913755A1 (es)
MX (1) MX2015016494A (es)
PH (1) PH12015502679A1 (es)
SG (2) SG10201709955PA (es)
TW (1) TW201536284A (es)
WO (1) WO2014194226A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017072699A1 (en) * 2015-10-28 2017-05-04 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CN105769766B (zh) * 2016-03-24 2018-07-06 长沙佰顺生物科技有限公司 一种托匹司他纳米乳及其制备方法
JP7108384B2 (ja) * 2016-07-13 2022-07-28 日本ケミファ株式会社 ２－［３－シアノ－４－（２－メチルプロポキシ）フェニル］－４－メチルチアゾール－５－カルボン酸の口腔内崩壊錠
CA3030821A1 (en) * 2016-07-18 2018-01-25 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
AU2020287549A1 (en) 2019-06-04 2022-01-27 Nippon Chemiphar Co., Ltd. Therapeutic for gout or hyperuricemia
JP2024520138A (ja) * 2021-06-15 2024-05-21 エルジー・ケム・リミテッド １－（３－シアノ－１－イソプロピル－インドール－５－イル）ピラゾール－４－カルボン酸を含む薬学的組成物
CN115252567A (zh) * 2022-07-08 2022-11-01 广西纯正堂制药有限公司 非布司他渗透泵缓释片及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5544163A (en) 1994-03-08 1996-08-06 Excel, Inc. Expandable telecommunications system
JP4084309B2 (ja) 2002-03-28 2008-04-30 帝人株式会社 単一の結晶形を含有する固形製剤
US7598254B2 (en) 2004-06-14 2009-10-06 Nippon Chemiphar Co., Ltd. Substituted 1,3-thiazolo[5,4-d]pyrimidines as xanthine oxidase inhibitors
WO2007043457A1 (ja) 2005-10-07 2007-04-19 Astellas Pharma Inc. トリアリールカルボン酸誘導体
JP2010516691A (ja) * 2007-01-19 2010-05-20 タケダ ファーマシーティカルズ ノース アメリカ，アイエヌシー． 抗炎症剤及びキサンチン酸化還元酵素阻害剤を用いて痛風の突発を抑え、又はその数を減少させる方法
SI2415771T1 (sl) * 2009-03-31 2013-12-31 Kissei Pharmaceutical Co., Ltd. Derivat indolizina in njegova uporaba v medicinske namene
CN101773498B (zh) * 2009-12-30 2012-06-20 青岛黄海制药有限责任公司 一种含有非布司他的口服缓控释制剂的制备方法
JP5865904B2 (ja) * 2010-06-16 2016-02-17 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド キサンチンオキシドレダクターゼ阻害剤またはキサンチンオキシダーゼ阻害剤の新規の調節放出剤形
AR081935A1 (es) 2010-06-16 2012-10-31 Teijin Pharma Ltd Tableta con nucleo recubierto de liberacion controlada
CN102641255A (zh) * 2012-05-08 2012-08-22 南方医科大学 一种治疗痛风的非布索坦渗透泵控释片及其制备方法

Also Published As

Publication number Publication date
WO2014194226A2 (en) 2014-12-04
JP2016520133A (ja) 2016-07-11
US20140357683A1 (en) 2014-12-04
CN105579037A (zh) 2016-05-11
SG11201509738RA (en) 2015-12-30
CA2913755A1 (en) 2014-12-04
WO2014194226A3 (en) 2015-05-14
PH12015502679A1 (en) 2016-03-07
TW201536284A (zh) 2015-10-01
SG10201709955PA (en) 2018-01-30
JP2019108356A (ja) 2019-07-04
US20180311217A1 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
PH12015502679A1 (en) Methods of treatment and compositions with xanthine oxidase inhibitors
PH12018500097A1 (en) Combination of pd-1 antagonist with an egfr inhibitor
PH12016501790A1 (en) Pharmaceutical compositions of therapeutically active compounds
PH12016502355B1 (en) Pharmaceutical composition
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
TN2017000554A1 (en) Novel combination for use in the treatment of cancer
PH12016501788A1 (en) Pharmaceutical compositions of therapeutically active compounds
ZA201700196B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
WO2014134583A3 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PH12016502352A1 (en) Pharmaceutical composition
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
TW201613578A (en) Pharmaceutical combinations
MX2022001796A (es) Metodos y composiciones para inhibir los sintomas asociados con la veisalgia.
PH12015501783A1 (en) Pharmaceutical compositions for the treatment of helicobacter pylori
EP4385563A3 (en) Dosage forms and therapeutic uses l-4-chlorokynurenine
MX2016016039A (es) Formulacion farmaceutica para reducir la frecuencia de micción y método para su utilización..
IN2014DN08443A (es)
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
IN2013MU02370A (es)
TN2014000418A1 (en) Methods for treating cancer using pi3k inhibitor and mek inhibitor
AR096513A1 (es) Métodos de tratamiento y composiciones con inhibidores de la xantina oxidasa
MY169877A (en) Treatment of malphigia coccigera on liver cirrhosis
EA201491695A1 (ru) Лечение рака ингибиторами tor-киназы
PL410457A1 (pl) Kompozycja farmaceutyczna zawierająca kwas dokozaheksaenowy oraz jej zastosowanie